Skip to content
Clinical Trials – home

Oncopole Claudius Regaud

Verified siteinfo

France 1 Avenue Irene Joliot Curie, 31059 Toulouse, France

  • 533 trials recruiting
  • Non-small cell lung cancer · Plasma cell myeloma · Neoplasm
  • Adults and children

About Specializations

Oncopole Claudius Regaud in Toulouse, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Plasma cell myeloma, Neoplasm, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms – Solid Tumor Oncology

Oncopole Claudius Regaud’s Medical Oncology department leads extensive research on solid tumors, aiming to test innovative therapies and improve patient outcomes across multiple cancer types.

  • Advanced breast cancer, including hormone‑receptor‑positive and HER2‑negative subtypes
  • Non‑small cell lung cancer (NSCLC) and rare thoracic malignancies
  • Gastro‑intestinal cancers such as colorectal, pancreatic, and gastric adenocarcinoma
  • Renal cell carcinoma and other kidney‑related neoplasms
  • Metastatic melanoma and cutaneous skin cancers

Over 400 active trials involve more than 300 investigators, reflecting a strong commitment to advancing treatment options for patients with advanced solid cancers.

Hematologic Malignancies

The site conducts a broad portfolio of studies on blood‑borne cancers, focusing on novel agents and transplantation strategies to enhance survival and quality of life.

  • Acute myeloid leukemia (AML) and related myelodysplastic syndromes
  • Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
  • Multiple myeloma, including transplant‑ineligible and relapsed disease
  • Aggressive B‑cell non‑Hodgkin lymphomas and diffuse large B‑cell lymphoma
  • Peripheral T‑cell lymphoma and other rare lymphoid disorders

These trials evaluate targeted therapies, immunotherapies, and stem‑cell transplantation to improve remission rates and reduce treatment‑related toxicity.

Targeted & Immunotherapy Research

A core focus at the centre is the development of precision medicine approaches, integrating molecular profiling with immunotherapeutic agents to treat resistant cancers.

  • Checkpoint inhibitors combined with chemotherapy or anti‑angiogenic drugs
  • PARP inhibitors for BRCA‑mutated breast and ovarian cancers
  • FGFR, ALK, ROS1, and BRAF targeted agents across multiple tumor types
  • Antibody‑drug conjugates for HER2‑low and HER2‑positive malignancies
  • Cellular therapies such as CAR‑T and engineered T‑cell products for hematologic cancers

By linking genomic alterations to specific drugs, the site seeks to personalize treatment and accelerate regulatory approval pathways.

Diagnostic Imaging & Molecular Profiling

Research at Oncopole Claudius Regaud includes advanced diagnostic techniques that guide therapeutic decisions and monitor disease progression.

  • 18F‑FES PET/CT for assessing estrogen‑receptor activity in breast cancer
  • ctDNA surveillance for early detection of molecular relapse
  • Multiplex next‑generation sequencing panels for tumor mutational profiling
  • Radiomic analysis of MRI and CT scans to predict treatment response
  • Biomarker validation for immune checkpoint efficacy across cancer types

These studies aim to refine patient selection, reduce unnecessary toxicity, and support adaptive trial designs.

Rare & Pediatric Oncology

The centre dedicates resources to rare and pediatric cancers, offering patients access to cutting‑edge trials that would otherwise be unavailable.

  • Pediatric medulloblastoma and high‑grade gliomas
  • Rare sarcomas such as chondrosarcoma and osteosarcoma
  • Germ‑cell tumors and testicular cancers with limited standard options
  • Peritoneal mesothelioma and thymic malignancies
  • Rare endocrine tumors including pheochromocytoma and paraganglioma

Collaborative networks and molecular screening enable enrollment in international protocols focused on efficacy and safety in these underserved populations.

Gynecologic & Urologic Cancers

A substantial portion of the trial portfolio addresses female urogenital and male urogenital diseases, exploring novel systemic and localized therapies.

  • High‑grade serous ovarian, fallopian tube and primary peritoneal cancers
  • Endometrial carcinoma, including mismatch‑repair deficient subtypes
  • Advanced prostate cancer, both hormone‑sensitive and castration‑resistant forms
  • Muscle‑invasive bladder cancer and upper urinary tract urothelial carcinoma
  • Cervical and vulvar cancers with targeted or immunotherapeutic approaches

Trials evaluate combination regimens, maintenance strategies, and biomarker‑driven therapies to improve survival and preserve organ function.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
1 Avenue Irene Joliot Curie31059 ToulouseFrance
Recruiting now
533 trials
Conditions studied
575
Partner status
Verified site

More sites in ToulouseFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

1 283 clinical trials

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

A Randomized Trial of lu af28996 dh1 to Reduce Motor Fluctuations in Adults with Parkinson’s Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LU AF28996 DH1
  • Sponsor:H. Lundbeck A/S

Narcolepsy

Recruiting

Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pitolisant
  • Sponsor:Harmony Biosciences Management Inc.

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.